New data on chemotherapy in the adjuvant setting

Breast

Volumn 12, Issue 6, 2003, Pages 373-378

  Piccart, Martine J ^a   Sotiriou, C ^a   Cardoso, F ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Adjuvant; Breast; Chemotherapy; Cyclin E; Genomic signatures; UPA PAI 1

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN E; CYCLOPHOSPHAMIDE; DNA; DOCETAXEL; DOXORUBICIN; MOLECULAR MARKER; PACLITAXEL; PLASMINOGEN ACTIVATOR INHIBITOR 1; TAMOXIFEN; UROKINASE;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER INVASION; CANCER STAGING; CLINICAL TRIAL; DNA MICROARRAY; FEMALE; FOLLOW UP; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; LYMPH NODE; MEDICAL DECISION MAKING; NEUROTOXICITY; NEUTROPENIA; PATIENT CARE; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; TUMOR GROWTH; VOMITING;

EID: 0345971293     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9776(03)00139-5     Document Type: Article

References (19)

1. National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000. National Institutes of Health Consensus Development Panel. J Natl Cancer Inst 2001; 93 (13): 979-989.
2. Goldhirsch A, Glick J H, Gelber R D, Coates A S, Senn H J. Meeting highlights: international consensus panel on the treatment of primary cancer. J Clin Oncol 2001; 19: 3817-3827.
3. Janicke F, Schmitt M, Graeff H. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemost 1991; 17: 303-312.
4. Janicke F, Schmitt M, Pache L et al. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 1993; 24: 195-208.
5. Harbeck N, Thomssen C, Berger U et al. Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up for primary breast cancer and following first relapse. Breast Cancer Res Treat 1999; 54: 147-157.
6. Foekens J A, Peters H A, Look M P et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 2000; 60: 636-643.
7. Harbeck N, Alt U, Kruger A et al. Prognostic impact of proteolytic factors (uPA, PAI-1, cathepsins B, D, L) in primary breast cancer reflects effects of adjuvant systemic therapy. Clin Cancer Res 2001; 7: 2757-2764.
8. Janicke F. Prechtl A, Thomssen C et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 2001;93: 913-920.
9. Zemzoum I, Kates R E, Ross J F et al. Invasion Factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer. J Clin Oncol 2003; 21: 1022-1028.
10. Look M P, van Putten W L J, Duffy M J et al. Pooled analysis of prognostic impact of uPA and PAI-1 in 8, 377 breast cancer patients. J Natl Cancer Inst 2002; 94: 116-128.
11. Harbeck N, Kates R, Schmitt M. Clinical relevance of invasion factors uPA and PAI-1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J Clin Oncol 2002; 20: 1000-1009.
12. Harbeck N, Kates R E, Look M P et al. Enhanced benefit from adjuvant systemic chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1). Cancer Res 2002; 62: 4617-4622.
13. Keyomarsi K, Tucker S L, Buchholz T A et al. Cyclin E and survival in patients with breast cancer. N Engl J Med 2002; 347(20): 1566-1575.
14. van't Veer L J, Dai H, van de Vijver M J et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-536.
15. Van de Vijver M J, He Y D, Van't Veer L J et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2003; 347(25): 1999-2009.
16. Sotiriou C, Neo S Y, Mc Shane L et al. Breast cancer classification and prognosis based on gene expression profiles from a population based study. Proceedings of the National Academy of Sciences 2003; in press.
17. Citron M L, Berry D A, Cirrincione C et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 974.J Clin Oncol 2003; 21(8): 1431-1439.
18. Norton L and Simon R: The Norton-Simon hypothesis revisited. Cancer Treat Res 1986; 70: 163-169.
19. Piccart-Gebhart M J. Mathematics and oncology: a match for life? J Clin Oncol 2003; 21(8): 1425-1428.